Predict cardiotoxicity, understand mechanisms of cardiac risk, and support regulatory decision-making using human-relevant in vitro cardiomyocyte models aligned with New Approach Methodologies (NAMs).
Integrated Multi-Parameter Cardiac Assessment
Replace multiple legacy assays including Multi-Electrode Array (MEA), standalone Calcium Transient, and Impedance Assays with a single, unified platform.
CellOPTIQ® is a cardiovascular NAM platform which simultaneously measures electrophysiology (voltage), calcium dynamics, and contractility in the same cells, providing a comprehensive view of cardiomyocyte function in a single experiment. This integrated approach delivers high-precision, functionally relevant data, enabling more accurate detection of cardiotoxicity and compound-specific effects.
By combining multiple functional readouts, CellOPTIQ® captures multi-ion channel effects and excitation–contraction coupling, key drivers of cardiotoxicity often missed by single-endpoint assays.
Aligned with New Approach Methodologies (NAMs) and Regualtory Guidance
Regulatory agencies, including the FDA, are shifting toward NAM-based approaches that integrate human-relevant in vitro systems and in silico modelling to improve prediction of cardiac risk.
CellOPTIQ® supports this transition by:
Using human cardiomyocytes (hiPSC-derived and adult)
Delivering integrated functional data (voltage, calcium, contractility)
Supporting CiPA-aligned proarrhythmic risk assessment
Reduce Cost, Time and Animal Testing
Screen compounds earlier using human-relevant models to identify cardiac risk before progressing to in vivo studies, improving efficiency and reducing late-stage failure.
CellOPTIQ® enables early-stage cardiac safety assessment prior to in vivo studies, helping reduce reliance on costly, time-consuming, and ethically challenging animal models.
This approach aligns with global efforts to reduce animal testing and adopt NAM-based strategies for safer and more sustainable drug development.
Mixed Ion Channel Effects - Verapamil
CellOPTIQ® captures mixed ion channel effects that influence cardiac risk, providing a more accurate assessment of proarrhythmic potential.
For example, compounds such as Verapamil exhibit multi-ion channel activity that mitigates proarrhythmic risk effects that are accurately captured by the platform.
Superior to Traditional Cardiac Assays
In a single experiment, CellOPTIQ® delivers the equivalent data generated by separate voltage, calcium, and contractility assays across a wider range of cell types and study conditions.
Flexible study design supports applications across drug discovery, safety pharmacology, and regulatory assessment.
Compared to traditional platforms such as MEA or patch clamp alone, CellOPTIQ® provides a more complete and translationally relevant understanding of cardiac function and drug effects.
What You Gain from integrating CellOPTIQ® into Your Cardiac Safety Strategy
Team of scientists who will work with you end-to-end from study design to submission
Predict cardiotoxicity earlier in development
Detect proarrhythmic risk with greater accuracy
Understand mechanisms of cardiac liability
Reduce reliance on animal testing (NAMs)
Generate data aligned with FDA and CiPA frameworks
Accelerate decision-making and reduce development costs
Request a Study Proposal Or contact us at info@clydebio.com